Stavudine: an update of its use in the treatment of HIV infection (Q33793229)

29 July 2017

1 reference

title

Stavudine: an update of its use in the treatment of HIV infection (English)

1 reference

29 July 2017

1 reference

M Hurst

1

1 reference

29 July 2017

S Noble

series ordinal

2

1 reference

29 July 2017

1 November 1999

1 reference

29 July 2017

1 reference

29 July 2017

58

1 reference

29 July 2017

5

1 reference

29 July 2017

919-949

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199958050-00012

29 July 2017

0 references

cites work

Dose proportionality of stavudine in HIV seropositive asymptomatic subjects: application to bioequivalence assessment of various capsule formulations

1 reference

12 December 2020

Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group

1 reference

12 December 2020

Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture

1 reference

12 December 2020

Guidelines for the use of antiretroviral agents in pediatric HIV infection. Center for Disease Control and Prevention

1 reference

12 December 2020

Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex

1 reference

12 December 2020

Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

1 reference

12 December 2020

Genotypic and phenotypic resistance to stavudine after long-term monotherapy. BMS-020 Spanish Study Group

1 reference

12 December 2020

A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors

1 reference

12 December 2020

Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection

1 reference

12 December 2020

Hydroxyurea as part of a salvage regimen for heavily pretreated patients with advanced HIV infection

1 reference

12 December 2020

A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus

1 reference

12 December 2020

Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro

1 reference

12 December 2020

Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use.

1 reference

12 December 2020

The role of stavudine in the management of adults with HIV infection

1 reference

12 December 2020

Evaluation of the combination effect of different antiviral compounds against HIV in vitro

1 reference

12 December 2020

Tetrazolium-based plaque assay for HIV-1 and HIV-2, and its use in the evaluation of antiviral compounds.

1 reference

12 December 2020

The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2',3'-didehydro-2',3'-dideoxyribonucleosides: a comparison with their parental 2',3'-dideoxyribonucleosides

1 reference

12 December 2020

Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains

1 reference

12 December 2020

Relevance of AIDS treatment with two nucleoside analogues alone

1 reference

12 December 2020

Pharmacokinetics and safety of a single dose of stavudine (d4T) in patients with severe hepatic impairment.

1 reference

12 December 2020

Guidelines for managing HIV infection

1 reference

12 December 2020

Metabolism and DNA interaction of 2',3'-didehydro-2',3'-dideoxythymidine in human bone marrow cells

1 reference

12 December 2020

Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex

1 reference

12 December 2020

Mitochondrial injury. Lessons from the fialuridine trial

1 reference

12 December 2020

A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance.

1 reference

12 December 2020

1 reference

12 December 2020

1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee

1 reference

12 December 2020

Synergistic inhibition of HIV-1 by an antisense oligonucleotide and nucleoside analog reverse transcriptase inhibitors

1 reference

12 December 2020

Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity

1 reference

12 December 2020

Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS.

1 reference

12 December 2020

Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus

1 reference

12 December 2020

Mutations in the human immunodeficiency virus type 1 reverse transcriptase gene observed in stavudine and didanosine strains obtained by in vitro passages

1 reference

12 December 2020

Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection

1 reference

12 December 2020

A multiple drug interaction study of stavudine with agents for opportunistic infections in human immunodeficiency virus-infected patients.

1 reference

12 December 2020

Favorable interaction of beta-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus

1 reference

12 December 2020

1 reference

12 December 2020

Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089.

1 reference

12 December 2020

Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects.

1 reference

12 December 2020

The transport of the anti-HIV drug, 2',3'-didehydro-3'-deoxythymidine (D4T), across the blood-brain and blood-cerebrospinal fluid barriers

1 reference

12 December 2020

Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine

1 reference

12 December 2020

Selective action of 2',3'-didehydro-2',3'-dideoxythymidine triphosphate on human immunodeficiency virus reverse transcriptase and human DNA polymerases

1 reference

12 December 2020

Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides

1 reference

12 December 2020

Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel

1 reference

12 December 2020

2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial

1 reference

12 December 2020

Riboflavine and severe lactic acidosis

1 reference

12 December 2020

Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro

1 reference

12 December 2020

Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication

1 reference

12 December 2020

Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patients

1 reference

12 December 2020

Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS

1 reference

12 December 2020

A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults.

1 reference

12 December 2020

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

1 reference

12 December 2020

"Buffalo hump" in men with HIV-1 infection.

1 reference

12 December 2020

Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy

1 reference

12 December 2020

Stavudine in zidovudine (ZDV)-experienced compared with ZDV-naive patients

1 reference

12 December 2020

Lack of emergence of genotypic resistance to stavudine after 2 years of monotherapy

1 reference

12 December 2020

Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides

1 reference

12 December 2020

Diminished HIV-1 sensitivity to stavudine in patients on prolonged therapy occurs only at low levels and cannot be attributed to any single amino acid substitution in reverse transcriptase

1 reference

12 December 2020

Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report

1 reference

12 December 2020

HIV research: a need to focus on the right target

1 reference

12 December 2020

Lamivudine-stavudine-induced liver failure in hepatitis B cirrhosis

1 reference

12 December 2020

Stavudine resistance: an update on susceptibility following prolonged therapy

1 reference

12 December 2020

Safety and efficacy of two different triple drug combinations in which either lamivudine or didanosine were administered with stavudine plus indinavir

1 reference

12 December 2020

Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection

1 reference

12 December 2020

Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro

1 reference

12 December 2020

Intracellular metabolism of zidovudine and stavudine in combination

1 reference

12 December 2020

Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy

1 reference

12 December 2020

Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells.

1 reference

12 December 2020

Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study

1 reference

12 December 2020

Salvage therapy with ritonavir-saquinavir plus two nucleoside reverse transcriptase inhibitors in patients failing with amprenavir-zidovudine-lamivudine

1 reference

12 December 2020

Effects of 2',3'-dideoxynucleosides on proliferation and differentiation of human pluripotent progenitors in liquid culture and their effects on mitochondrial DNA synthesis

1 reference

12 December 2020

The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.

1 reference

12 December 2020

High prevalence of multiple drug resistance mutations in a UK HIV/AIDS patient population

1 reference

12 December 2020

Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection

1 reference

12 December 2020

3'-Deoxythymidin-2'-ene permeation of human lymphocyte H9 cells by nonfacilitated diffusion

1 reference

12 December 2020

The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus

1 reference

12 December 2020

Stavudine-induced macrocytosis during therapy for human immunodeficiency virus infection

1 reference

12 December 2020

Clinical HIV-1 isolates remain sensitive to stavudine following prolonged therapy

1 reference

12 December 2020

Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus

1 reference

12 December 2020

Kinetics of tumor necrosis factor alpha and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didanosine, and hydroxyurea

1 reference

12 December 2020

Antiretroviral activity of stavudine (2',3'-didehydro-3'-deoxythymidine, D4T).

1 reference

12 December 2020

Cellular pharmacology of 2',3'-didehydro-2',3'-dideoxythymidine (D4T) in human peripheral blood mononuclear cells

1 reference

12 December 2020

Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro.

1 reference

12 December 2020

Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy

1 reference

12 December 2020

Anti-HIV-1 activity of antiviral compounds, as quantitated by a focal immunoassay in CD4+ HeLa cells and a plaque assay in MT-4 cells

1 reference

12 December 2020

Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences

1 reference

12 December 2020

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

1 reference

12 December 2020

Stavudine, lamivudine and indinavir in children with advanced HIV-1 infection: preliminary experience

1 reference

12 December 2020

1 reference

12 December 2020

Immunopathogenic mechanisms of HIV infection

1 reference

12 December 2020

A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study

1 reference

12 December 2020

Stavudine induced macrocytosis

1 reference

12 December 2020

Clinical pharmacokinetics of stavudine

1 reference

12 December 2020

A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team

1 reference

12 December 2020

The ex vivo transfer of the anti-HIV nucleoside compound d4T in the human placenta

1 reference

12 December 2020

1 reference

12 December 2020

HIV inhibitors targeted at the reverse transcriptase

1 reference

12 December 2020

Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication

1 reference

12 December 2020

Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group

1 reference

12 December 2020

Gynecomastia with stavudine treatment in an HIV-positive patient

1 reference

12 December 2020

Synthesis and anti-HIV activity of some novel chain-extended phosphoramidate derivatives of d4T (stavudine): esterase hydrolysis as a rapid predictive test for antiviral potency

1 reference

12 December 2020

Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway

1 reference

12 December 2020

Mitochondrial toxicity of antiviral drugs

1 reference

12 December 2020

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team

1 reference

12 December 2020

cycloSal-2',3'-dideoxy-2',3'-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system

1 reference

12 December 2020

Viral dynamics in human immunodeficiency virus type 1 infection

1 reference

12 December 2020

Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation

1 reference

12 December 2020

Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compounds

1 reference

12 December 2020

10.2165/00003495-199958050-00012

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

1009789722

0 references

Fatcat ID

release_tstz55fb3bde5drdg5kknnnz3i

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tstz55fb3bde5drdg5kknnnz3i

24 November 2022

mapped directly with Wikidata item

1 reference